DIRS.INFO The most relevant business & tech news

☆ Here are Friday's biggest analyst calls: Nvidia, Tesla, Apple, Rivian, Micron, Microsoft, Eli Lilly, Amazon & more
▼ + stars: | 2024-03-15 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Citi upgrades Thor Industries to buy from neutral Citi said it see a "favorable event path" for the RV company. " Citi initiates Pure Storage as buy Citi said in its initiation of Pure Storage that the data storage company is an AI beneficiary. Citi reiterates Apple as buy Citi said it's standing by its buy rating on shares of Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon's Spring Sales event next week. Citi reiterates Micron as buy Citi raised its price target on the stock to $150 per share from $95 and says it's bullish heading into earnings next week. "

Persons: Piper Sandler, Piper, Morgan Stanley, RSG, Cummins, Baird, Nvidia, JPMorgan, Tesla, Telsey, Todd Vasos, it's, Stellantis, Five9, PBF, DINO, Truist, Eli Lilly, LLYs, Dave Ricks, Patrik Jonsson Organizations: EV, Bank of America, Adobe, Citi, Thor Industries, Morgan Stanley downgrades Republic Services, UBS, Cummins, CMI, Microsoft, Nvidia, JPMorgan, Guggenheim, Apple, Worldwide, " Bank of America, Micron, Catalyst Watch, RBC, UFC, WWE, Inc, Valero Energy, Sinclair, of America, Entertainment, Golden Entertainment, Diabetes, Obesity Locations: Snowflake, F4Q24, China, Nevada

☆ Getting hot new weight-loss drugs like Wegovy will still be a struggle in 2024
▼ + stars: | 2024-01-04 | by ( ) www.businessinsider.com time to read: +11 min

AdvertisementIf you were hoping that powerhouse weight-loss drugs like Wegovy would be easier to get in 2024, you may be disappointed. Don't expect Medicare coverage any time soonMedicare could play a major role in expanding coverage of weight-loss drugs . Americans' hunger for weight-loss drugs, and the shockwaves it's likely to send through the culture and economy, are only just beginning. He oversees the state employee health plan, which saw costs skyrocket as thousands of workers suddenly started taking weight-loss drugs. People who are already getting weight-loss drugs will be able to keep taking them.

Persons: —, Renee Rayburg, Mercer, Eli Lilly's, Jose Luis Pelaez, there's, Wegovy, Bill Coyle, ZS, Eli Lilly, David Risinger, Lilly, Risinger, Morgan Stanley, Mounjaro, They're, That's, Patrik Jonsson, Lilly USA, Coyle, Dale Folwell, Folwell Organizations: Service, Pharmaceutical, Group, Novo Nordisk's Wegovy, Mayo Clinic, University of Texas, Hennepin Healthcare, Medicare, Capital Alpha Partners, Vanderbilt University, Nordisk's Wegovy, Novo Nordisk, pharma, Nordisk's, FDA, Pharma, UBS BioPharma Conference, Walmart, Jefferies, Nordisk Locations: Mounjaro, Government, Minnesota, Minneapolis, Hennepin, ZS, U.S, Carolina, North Carolina

☆ Eli Lilly appoints new obesity unit head ahead of key Mounjaro decision
▼ + stars: | 2023-10-04 | by ( Reuters Staff | ) www.reuters.com time to read: +1 min

(Reuters) -Eli Lilly and Co on Wednesday appointed a new chief for its diabetes and obesity unit in a string of leadership changes ahead of a key regulatory decision on the use of its potential blockbuster drug Mounjaro as a weight-loss treatment. Slideshow ( 2 images )Mounjaro, chemically known as tirzepatide, is already being prescribed by doctors off-label as an obesity treatment. In his new role, Jonsson will oversee Lilly’s launched products and late-stage development of diabetes and obesity treatments, including tirzepatide and other candidates such as its next-generation obesity drug retatrutide and obesity pill orforglipron. Mason, who has also spent more than three decades with Lilly, oversaw the late-stage development and the launch of Mounjaro. The diabetes drug, which clocked in sales of $979.7 million in the latest quarter, belongs to a class of drugs known as GLP-1s that stimulate insulin production.

Persons: Eli Lilly, Patrik Jonsson, Lilly USA, Mike Mason, Jonsson, Lilly’s, Mason, Lilly, Daniel Skovronsky Organizations: Reuters Locations: Sweden, Scandinavia, Italy, Japan, Jonsson

☆ Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
▼ + stars: | 2023-06-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Eli Lilly on Tuesday said it struck a $2.4 billion deal to acquire Dice Therapeutics in a bid to bulk up its treatment portfolio for immune-related diseases. Dice Therapeutics' share price jumped more than 37% to just under the purchase price. Auto-immune diseases can causes pain, fatigue, dizziness, depression and rashes, among other symptoms. There are more than 100 known autoimmune diseases, including lupus, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Eli Lilly's immunology portfolio includes drugs like Taltz, which treats plaque psoriasis, and Olumiant, a treatment for rheumatoid arthritis.

Persons: Eli Lilly, Eli Lilly's, Patrik Jonsson, Eli, Taltz Organizations: Dice Therapeutics Locations: Francisco

Search resuls for: "Patrik Jonsson"

4 mentions found